EGFR and non-small cell lung carcinoma: The efficacy of osimertinib in EGFR-mutated NSCLC patients harboring exon 20 insertion mutations (up to 12% of mutated EGFR) is limited and this population can benefit from mobocertinib, a C797 covalent EGFR inhibitor, which may be resistant to C797S mutations as well [23,24,25].